Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Has Consensus Price Target of $129.83

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has earned a consensus rating of “Moderate Buy” from the fifteen analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, thirteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $129.83.

Several analysts have recently issued reports on DNTH shares. Truist Financial increased their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Citigroup initiated coverage on Dianthus Therapeutics in a research note on Friday, September 4th. They issued a “buy” rating and a $156.00 price target for the company. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Finally, JPMorgan Chase & Co. started coverage on shares of Dianthus Therapeutics in a research note on Friday, September 11th. They set an “overweight” rating and a $135.00 price objective on the stock.

Insider Transactions at Dianthus Therapeutics

In other news, Director Anne McGeorge sold 7,750 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.01, for a total transaction of $844,827.50. Following the completion of the sale, the director owned 1,250 shares of the company’s stock, valued at approximately $136,262.50. This represents a 86.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Simrat Randhawa sold 23,124 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $425,640. This trade represents a 85.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 242,429 shares of company stock worth $26,118,913. Corporate insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Dianthus Therapeutics during the 2nd quarter worth approximately $401,990,000. Wellington Management Group LLP lifted its stake in Dianthus Therapeutics by 24.4% in the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock valued at $314,849,000 after purchasing an additional 634,099 shares during the last quarter. Jennison Associates LLC bought a new position in Dianthus Therapeutics in the 1st quarter valued at approximately $40,713,000. Spruce Street Capital LP bought a new position in Dianthus Therapeutics in the 2nd quarter valued at approximately $34,587,464. Finally, Assenagon Asset Management S.A. acquired a new stake in Dianthus Therapeutics in the second quarter valued at approximately $27,358,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH opened at $81.57 on Thursday. The company has a market capitalization of $4.47 billion, a P/E ratio of -19.66 and a beta of 1.35. Dianthus Therapeutics has a 1 year low of $32.22 and a 1 year high of $117.88. The business’s 50 day simple moving average is $102.17 and its 200 day simple moving average is $94.55.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. On average, sell-side analysts anticipate that Dianthus Therapeutics will post -3.81 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.